GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Sponsor: AstraZeneca
A PHASE3 clinical study on Coronary Artery Disease (CAD), this trial is completed. The trial is conducted by AstraZeneca and has accumulated 11 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE3
-
Jan 2019 — Aug 2019 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Biosensors International
- ECRI bv
- The Medicines Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Aix-en-Provence, France , Alkmaar, Netherlands , Amsterdam, Netherlands , Arezzo, Italy , Bad Krozingen, Germany , Bad Nauheim, Germany , Balatonfüred, Hungary , Barcelona, Spain , Belfast, United Kingdom and 96 more locations